We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WKL:EURONEXT AMSTERDAMWolters Kluwer N.V. Analysis

Data as of 2026-07-27 - not real-time

€65.62

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Wolters Kluwer is trading at €65.62, well above its DCF fair value of €42.36, suggesting the stock is currently overvalued despite a low P/E of 11.6 versus the industry average of 31.3. The company posted a modest revenue growth of 1.6% and strong profitability margins (gross 73%, operating 24%), while generating robust free cash flow of €985.5 m that comfortably covers its 4.03% dividend yield and a payout ratio of 43%. Recent share‑buyback activity—repurchasing over 110,000 shares for €6.2 m at an average price of €56.24—adds a modest price‑support catalyst and signals confidence from management. Technicals show the price hovering near the resistance level of €65.76, with the 20‑day SMA at €60.35, an RSI of 66 (near overbought), a bullish MACD divergence, but a bearish overall trend and decreasing volume, indicating short‑term pressure. Volatility remains high at 33.5% over the past 30 days and the historical max drawdown sits at -59%, underscoring the need for caution.
Given the solid cash generation, sustainable dividend, and ongoing buy‑back program, the stock presents a compelling case for long‑term, dividend‑focused investors, though the current price premium and technical overbought signals advise a more defensive stance in the near term.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • RSI near overbought levels (66)
  • Price at resistance (€65.76) with bearish trend
  • Decreasing volume indicating weakening momentum

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Ongoing share buyback program supporting price
  • Strong dividend yield (4.03%) with sustainable payout
  • Stable cash flow and low beta reducing market sensitivity

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Consistent free cash flow generation
  • Attractive dividend and low payout ratio
  • Buyback activity indicating management confidence

Key Metrics & Analysis

Financial Health

Revenue Growth1.60%
Profit Margin21.36%
P/E Ratio11.6
ROE111.65%
ROA10.01%
Debt/Equity623.06
P/B Ratio18.6
Op. Cash Flow€1.7B
Free Cash Flow€985.5M
Industry P/E31.4

Technical Analysis

TrendBearish
RSI66.0
Support€54.68
Resistance€65.76
MA 20€60.35
MA 50€60.59
MA 200€75.22
MACDBullish
VolumeDecreasing
Fear & Greed Index90

Valuation

Fair Value€42.36
Target Price€91.70
Upside/Downside39.74%
GradeOvervalued
TypeValue
Dividend Yield4.03%

Risk Assessment

Beta-0.01
Volatility33.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.